Perceived risk and vaccine hesitancy: Quasi‐experimental evidence from Italy

Claudio Deiana, Andrea Geraci, Gianluca Mazzarella and Fabio Sabatini

Health Economics, 2022, vol. 31, issue 6, 1266-1275

Abstract: In March 2021, Italian health authorities suspended the Vaxzevria vaccine (VA) for 4 days over reports of very rare blood disorders among recipients. We exploit the quasi‐experimental setting arising from this break to study the drivers of vaccine hesitancy. Before the suspension, the VA vaccination trend followed the same pattern as Pfizer‐Biontech (PB). After the suspension, VA and PB injections started to diverge, with VA daily decreasing by almost 60 doses per 100,000 inhabitants for the following 3 weeks. The resulting vaccination rate was 60 percent lower than the value that would have stemmed from the VA pre‐suspension pattern. We show that the slowdown was weaker and less persistent in regions with higher COVID penetration and steadier and more pronounced in regions displaying greater attention to vaccine side effects as detected through Google searches. The public's interest in vaccine adverse events negatively correlates with COVID cases and deaths across regions.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://doi.org/10.1002/hec.4506

Related works:
Working Paper: Perceived risk and vaccine hesitancy: Quasi-experimental evidence from Italy (2021)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:31:y:2022:i:6:p:1266-1275

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().